Congratulations!

2017 We Care Fund Grant Recipient

Amanda L. Kong, MD, MS
Associate Professor, Division of Surgical Oncology
Prevention of Side Effects in Use of Chemotherapy in Breast Cancer

Symptomatic toxicity secondary to chemotherapy or targeted therapies are often managed throughout treatment and resolve or decrease upon cessation of treatment. At other times, severe or late onset consequences persist after completion of therapy and effective management strategies are lacking. This study will research mechanisms of chemotherapy-induced cardiotoxicity in breast cancer.

Amanda L. Kong, MD, MS
Associate Professor, Division of Surgical Oncology
Congratulations!

2017 We Care Fund Grant Recipient

T. Clark Gamblin, MD, MS, MBA

Stuart D. Wilson, MD, Professor and Chief, Division of Surgical Oncology
Liver cancer is one of the most common and lethal forms of cancer worldwide, which typically develops in cirrhotic livers associated primarily with hepatitis or ethanol damage. This novel and innovative study uses a natural compound and synthesized drug analog against liver cancer. The hope is the results of this study lead to the development of a clinical trial at MCW.
Congratulations!

2017 We Care Fund Grant Recipient

Viktor Hraska, MD, PhD

Professor and Chief, Pediatric Congenital Cardiac Surgery
Medical Director, Cardiothoracic Surgery, Children’s Hospital of Wisconsin
The casualty of brain injury in neonates is multifactorial. A myriad of factors are suggested to correlate with adverse neurological outcomes, which include congenital brain abnormalities, intrauterine accidents, pre and post-operative hemodynamic instability, intraoperative insults, as well as those caused by medical examination. This study will assess the effectiveness in newborns, infants, and children regarding adequate oxygen delivery, identify optimal neuro/somatic protective perfusion parameters, demonstrate technical feasibility and safety, and evaluate neurodevelopmental outcomes long-term in patients receiving full body perfusion during arch reconstruction operations.

**Improving Neurological Outcomes in Children During Open Heart Surgery**

Viktor Hraska, MD, PhD
Professor and Chief, Pediatric Congenital Cardiac Surgery
Medical Director, Cardiothoracic Surgery, Children’s Hospital of Wisconsin
THE WE CARE FUND ALSO PRESENTS
THE FOLLOWING CANDIDATES FOR GRANT FUNDING OPPORTUNITIES
Quality Improvement in Neonatal Intensive Care Units in Wisconsin

Currently in Wisconsin, significant variability of care exists among centers with respect to prevention, diagnosis, and treatment of infants with surgical conditions. We would like to create a regional collaborative of Level II and IV neonatal intensive care units to establish standards and consensus of care in patients with necrotizing enterocolitis (NEC). Create a database to monitor compliance to the collaborative’s standards, and track patient outcomes. The database will be used to guide medical and surgical care for infants with NEC.

Marjorie J. Arca, MD
Professor, Division of Pediatric Surgery
Personalized Therapy for Curing Metastatic Breast Cancer

Despite improvements in anticancer therapies, 20% of breast cancer patient succumb to metastatic disease that is resistant to current therapies each year. This study will personalize treatment of existing metastatic breast cancer to identify mechanisms of therapy resistance using patient-derived xenograft models; a unique model of the patient’s tumor tissue biologically replicated across multiple animals, enabling drug testing and mechanistic studies.

Michael Flister, PhD
Assistant Professor; Department of Physiology, Human and Molecular and Genetics Center
Pancreatic ductal adenocarcinoma (PDA) is a highly aggressive cancer due to unchecked tumor proliferation, metastasis, and therapeutic resistance. PDA is the most commonly form of pancreatic cancer and has an abysmal 5-year survival rate of 7%. For the minority of patients with localized disease, surgical intervention provides short-term benefit, but provides no reassurance for prevention of disease recurrence nor extended long-term survival. This project will study therapeutic approaches to mitigate the progression of malignant tumor grown as part of a multi-modal treatment strategy.

Michael B. Dwinell, PhD
Professor, Microbiology and Immunology, Department of Surgery
Discovering New Therapies for Endocrine Resistance Breast Cancer

Breast cancer is the most common carcinoma in women and the second most common cause of cancer death in females. This innovative study will, for the first time, define NgBR as a critical player in determining the susceptibility of ER+ breast cancer to tamoxifen, and will provide a knowledge guide for future therapeutic design. If successful, this study will lead to the development of new pharmacological strategies for treating ER+ breast cancers.

Qing (Robert) Miao, PhD
Associate Professor, Division of Pediatric Surgery
INTERESTED IN SUPPORTING A FUNDING OPPORTUNITY?

DONATE ONLINE AT mcw.edu/wecare